Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure ...United Arab Emirates

CNBC - Economy
Novo Nordisks next-gen obesity drug CagriSema had investors excited. Now theyre not so sure
Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure )

Apple Storegoogle play

Also on site :



Latest News